Pre-treatment with P2Y12 inhibitors in acute myocardial infarction with cardiogenic shock
In patients with AMI-CS, pretreatment with a P2Y12 inhibitor oral load was associated with an increased risk of major bleeding without benefit on MACE.
Authors
- Frederic Beaupré (ORCID: https://orcid.org/0000-0003-0630-3144)
- Patrick Ecollan
- David Sulman (ORCID: https://orcid.org/0000-0002-9400-1324)
- Gilles Montalescot (ORCID: https://orcid.org/0000-0003-0824-6809)
- Juliette Chommeloux
- Nassim Braik
- Stéphanie Rouanet (ORCID: https://orcid.org/0009-0003-5812-3599)
- Johanne Silvain (ORCID: https://orcid.org/0000-0002-1901-2808)
- Perrine Devos (ORCID: https://orcid.org/0000-0002-2677-3242)
- Michel Zeitouni (ORCID: https://orcid.org/0000-0001-9562-3128)
- P Charleux
- Alain Combes (ORCID: https://orcid.org/0000-0002-6030-3957)
- Mathieu Kernéis (ORCID: https://orcid.org/0000-0002-7141-5209)
- Niki Procopi (ORCID: https://orcid.org/0000-0001-7700-0744)
- Louis Giovachini (ORCID: https://orcid.org/0009-0003-3562-813X)
- Anthony Elhadad
Institutions
- Inserm (FR)
- Sorbonne Université (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
Publication Details
- Journal
- European Heart Journal - Cardiovascular Pharmacotherapy
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1093/ehjcvp/pvaf019
- Citations
- 1
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.39